BridgeBio Pharma Inc [BBIO] stock prices are up 6.46% to $45.98 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BBIO shares have gain 7.48% over the last week, with a monthly amount glided 19.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Pharma Inc [NASDAQ: BBIO] stock has seen the most recent analyst activity on July 09, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $60 for it. Previously, Wolfe Research started tracking the stock with Outperform rating on June 17, 2025, and set its price target to $49. On March 31, 2025, Redburn Atlantic initiated with a Buy rating and assigned a price target of $50 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating. Oppenheimer initiated its recommendation with a Perform. Piper Sandler started tracking with a Overweight rating for this stock on September 04, 2024, and assigned it a price target of $46.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.72 and $45.48 over the past year. Currently, Wall Street analysts expect the stock to reach $72 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $45.98 at the most recent close of the market. An investor can expect a potential return of 56.59% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 127.42M for trailing twelve months, representing a drop of -44.76%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -5.48%, Pretax Profit Margin comes in at -5.29%, and Net Profit Margin reading is -5.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is 0.49 and Total Capital is -0.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.45 points at the first support level, and at 42.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.97, and for the 2nd resistance point, it is at 47.96.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 4.57. Also, the Quick Ratio is 4.54, while the Cash Ratio stands at 3.55. Considering the valuation of this stock, the price to sales ratio is 68.52.
Transactions by insiders
Recent insider trading involved Kumar Neil, Chief Executive Officer, that happened on Jul 02 ’25 when 40000.0 shares were sold. Chief Executive Officer, Kumar Neil completed a deal on Jul 01 ’25 to sell 40000.0 shares. Meanwhile, 10% Owner VIKING GLOBAL INVESTORS LP sold 3.5 million shares on Jun 27 ’25.
